Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $2.5
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $4 to $2.5.
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $4 to $2.5.